Virtual Mentor

Virtual Mentor. January 2014, Volume 16, Number 1: 49-56.

Health Law

  • Print
  • |
  • View PDF

Fully Informed Consent for Prospective Egg Donors

In seeking informed consent from egg donors, the goal must be enabling them to make fully informed decisions, not merely securing pro forma consent.

Naomi Cahn, JD, and Jennifer Collins, JD

Jessica saw the ads on her college campus: egg donor wanted, high SAT scores, willing to pay, contact Egg Donors R Us. She was a financially struggling college junior, and the idea of helping people have children appealed to her. She called Egg Donors R Us and, after the receptionist asked her a few questions, she was invited to come to the clinic and fill out a questionnaire. It asked, for example, if she had dimples and freckles but not if she understood the medical procedures or risks involved in egg donation. She was given a provisional acceptance, had an interview with a nurse and a psychological consultant, and then had blood drawn for final eligibility checks.

A few months later, she was matched with a recipient and finally given the clinic’s informed consent form. She barely looked at it before signing; she was excited to begin the process that would help another woman as well as pay her tuition bills.

So just what did Jessica sign? What did it tell her? What legal requirements surround the informed consent form for donating eggs and sperm? Although approximately 12 percent of all assisted reproductive cycles in the United States (more than 18,000 cycles each year) involve donor eggs [1], and countless pregnancies are achieved every year using donor sperm, the donation process is only lightly regulated, particularly in the realm of informed consent.

Regulations

The federal regulations that do exist fall into two categories: safety testing and truth in advertising. Neither deals directly with informed consent. With regard to safety testing, donor gametes—sperm, eggs, and embryos—are regulated by the FDA under the category of human cells, tissues, and cellular and tissue-based products (HCT/Ps) [2, 3]. The applicable regulations focus on donor testing and record keeping and require that all entities handling sperm, eggs, or embryos register with the FDA [4, 5]. In addition, the FDA requires screening for each donor that includes a physical examination and a medical history interview [6]. With very limited exceptions, donors are also subject to testing aimed primarily at preventing communicable diseases [7]. Following the testing, semen must be frozen and quarantined, to be released six months later when certified as “disease-free.” States may impose their own licensing requirements above and beyond the federal regulations [8].

A second set of federal requirements, based on the 1992 Fertility Clinic Success Rate and Certification Act, focuses on truth in advertising and relates primarily to reporting requirements by fertility centers engaging in assisted reproductive technology (defined as the manipulation of both eggs and sperm) to ensure that clinics are not claiming inaccurate pregnancy rates [9]. These truth-in-advertising laws do not regulate entities that only handle sperm.

Because no federal laws regulate the informed consent process by, for example, specifying what information donors must be given before they provide gametes, the conscientious fertility center must look elsewhere.

One possible source is the American Society for Reproductive Medicine (ASRM), the self-regulatory association for assisted reproductive technology (ART) professionals, which has developed recommendations applicable to sperm, egg, and embryo donations. Unlike the FDA’s, which apply only to donors, the ASRM’s guidelines address both donors and recipients [10]. The ASRM, of course, has no enforcement authority apart from excluding noncomplying entities from membership. Accordingly, it “strongly recommends” rather than mandates.

Psychological evaluation and counseling are strongly recommended for donors, and genetic evaluation “should” be performed [11]. If a psychological assessment is done, then the guidelines recommend that it “ensure that the donor has been informed about all relevant aspects of the medical treatment” [12]. With respect to the possibility of identity disclosure, the guidelines note that the assessment should determine whether the donor has been “well informed about the extent to which information about [him or her may] be disclosed and about any plans that may exist relating to future contact” [13]. In short, the guidelines are detailed about the type of testing to be performed, but provide only summary recommendations concerning the scope and details of psychological counseling and evaluation that are recommended.

Finally, a few states have laws specifically focused on the egg-donation consent process [14]. Since 2010, egg donors in Arizona must be provided with specific information about the hormones they will be taking, the surgical procedures, and the risks [15]. California also has specific requirements concerning most steps involved in egg donation, requiring all entities that post advertisements offering “financial payment or compensation of any kind” for oocyte donation to certify that they have complied with ASRM requirements or include a notice stating:

Egg donation involves a screening process. Not all potential egg donors are selected. Not all selected egg donors receive the monetary amounts or compensation advertised. As with any medical procedure, there may be risks associated with human egg donation. Before an egg donor agrees to begin the egg donation process, and signs a legally binding contract, she is required to receive specific information on the known risks of egg donation. Consultation with your doctor prior to entering into a donor contract is advised [16].

New York has imposed requirements that the donor receive information about the “risks of any drugs, surgical procedures and/or anesthesia administered,” as well as the potential uses of the gametes [17].

Analysis

In this haphazard array of guidelines and state laws, the value of informed consent may be easy to overlook, but it is vitally important for several key reasons. First, state health care and tort law (particularly in the form of medical malpractice law) require informed consent to ensure that patients are involved in their own medical decision making, and physicians face tort liability for a failure to obtain informed consent. While there are problems with informed consent procedures in the United States—for example, the focus is on the physician providing information, rather than ensuring patient understanding [18]—the general principle is to promote patient autonomy. The focus of informed consent in ART has so far been on egg donors, but sperm donors also need adequate information to consent to the procedures.

Second, certainly for egg donors, donation involves potential risks. In one of the few studies of egg donors, the authors found that only a third knew about the possibility of ovarian hyperstimulation, only one-fifth knew about the possibility of infertility and the risk associated with the egg collection procedure, and only one in eight knew about the risks from the anesthesia used during egg recovery [19]. When it came to psychological aspects of the donation process, less than a third anticipated that they might feel a sense of loss or any type of emotional connection to their donated eggs or the resulting children, and only five percent were aware of the risk that a child might try to find them [19]. In addition, there is little research on the long-term impact of egg donation, including psychological aspects, and informed consent to unknown risks is particularly problematic.

Finally, gamete donation differs from most other medical procedures in three critical ways:

The end result is the creation of a child. Both egg and sperm donors may report complex emotions about their feelings towards resulting children [20, 21], and, notwithstanding promises of anonymity, donors may become interested in searching for offspring and offspring may search for their donors [22]. But the federal regulations say nothing about identity disclosure, and, as discussed earlier, even the ASRM guidelines only briefly mention disclosure, given that their primary foci are safety and recruitment, not the children who are born from donor gametes.

Egg donation is a medical procedure that involves significant medical risk yet provides no medical benefit to the donor. Indeed, the procedure is being done for someone else’s benefit. The most analogous situation is that of a living organ donor (although organ donation is not compensated). The Organ Procurement and Transplantation Network takes this risk so seriously that it requires provision of an independent donor advocate to ensure donors understand, among other issues, that they “will undertake risk and will receive no medical benefit from the operative procedure of donation” [23].

Decisions regarding egg donation can be impacted by outside sources. Just as the organ transplant donor’s decision may be influenced by pressure from family members, prospective egg donors can be influenced by external factors, particularly the potentially distorting factor of financial payment. The importance of financial compensation in egg donors’ decision-making processes is plainly demonstrated by the fact that countries that have banned the practice of compensation for egg donors have faced significant egg shortages [24]. Yet the ASRM guidelines barely mention this issue. They only urge the minimization of the amount of payment so donors are not “unduly induce[d]” and evaluation for coercion during the psychological assessment, but do not suggest including a discussion of this issue in the informed consent process so donors can consider whether their judgment is in fact being impacted by the promise of financial reward.

Recommendations

So what is a reasonable fertility center to do when it comes to donors? (Disclosure to recipients is important but is outside the scope of this article.) At the least, centers should mandate counseling and, potentially, even require the use of independent donor advocates during an informed consent process comparable to the one used in the context of organ donation. The informed consent forms should ensure not only that information is conveyed but also that the donor understands and is making the decision voluntarily [25]. For example, an intriguing new tool provides feedback on whether prospective donors comprehend the information they have received [25]. To develop that tool, researchers adapted a validated questionnaire used for cancer patients enrolling in clinical trials to assess whether egg donors had both a subjective and objective appreciation of the donation process, that is, “how well informed the donor feels about” the egg donation process and the “facts and concepts relevant to oocyte donation” [26]. The tool proved both reliable and readable—a common challenge for many medical documents—in pilot testing at the UCSF Center for Reproductive Health [25], and it would be useful in evaluating existing consent forms. In addition, the informed consent process should start at the time of initial screening and agreement to participate rather than later in the process, when a donor may already feel psychologically invested in seeing the donation process through to completion.

At a minimum, counseling should cover the following points, all of which should also be addressed in writing in the informed consent documentation:

  1. Detailed medical risks. While the ASRM guidelines do recommend disclosure of the risks involved, they do not specify what the disclosure must include [27]. Although there are essentially no risks for sperm donors, the medical risks for egg donors are significant and need to be adequately addressed. The information provided should go beyond the basic acknowledgement that there is “a small risk (1 in 200 women) of developing ovarian hyper-stimulation syndrome (OHSS)” and include details about the symptoms of the syndrome and under what circumstances a woman should call the clinic. In addition, donors must be told that there has been very little research about the long-term impact of egg donation and at least some physicians believe infertility and death are possible risks [28, 29].
  2. Information about whether donor eggs may be used for research purposes. A recent study concluded that only a small percentage of clinics inform potential donors that their eggs may be used for research, including stem cell research, and recommended that, in light of the moral or religious objections some donors may have, this information be disclosed in plain language in informed consent documents [30]. The ASRM urges that informed consent be obtained from donors if egg sharing is “contemplated” [31].
  3. A warning about the risks of multiple donations and donating at multiple clinics. There is currently no mandatory nationwide egg donor registry in the United States and no coordination between different clinics. Thus, it is quite possible for a woman to donate eggs at more than one clinic. This poses risks in two ways. First, it is believed that the medical risks increase with the number of cycles [32]. Second, donating at more than one clinic increases the possibility of creating unknown half-siblings [33].
  4. Confidentiality issues. The ASRM guidelines currently state only that donors “should be assured that their confidentiality will be protected insofar as federal and local statutes permit” [34]. This essentially provides the donors with no information at all. Donors should be informed that: (a) current regulations are subject to revision; (b) children resulting from their donation may one day contact them; and (c) donors have been identified even when clinics and donors have attempted to maintain confidentiality through registries. Donors should also be informed whether or not they have control over potential recipients.
  5. Compensation. A frank discussion of the possibility that the promise of significant financial payment may be influencing the donor’s assessment of risk, and disclosure of who is paying the fees for counseling and legal services—if it is the clinic, for example, that fact needs to be disclosed to donors. This discussion could occur while addressing the donor’s motivations. Money will certainly figure as one reason for donating; the important issue is assuring that there is no coercion.

Although fertility centers should take these steps voluntarily, legal regulation must provide the enforcement necessary to ensure uniform implementation. Self-regulation works much of the time, but not always [35]. Studies increasingly show that, at least with respect to egg donation, even fertility centers that are located in California, with its legal requirements for egg-donor advertisements, and that are members of the Society for Assisted Reproductive Technologies are not in full compliance when it comes to advertising and information disclosure [36, 37]. While professional standards are critical to promoting good medical care, outside monitoring will protect gamete donors, recipients, and children.



References

  1. Centers for Disease Control and Prevention. Section 4: ART cycles using donor eggs. In: Assisted Reproductive Technology (ART) 2010 National Summary Report. http://www.cdc.gov/art/ ART2010/section4.htm. Accessed September 8, 2013.
  2. US Food and Drug Administration. How do I screen a donor? 21 CFR sec 1271.75 (2006). http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?fr=1271.75. Accessed November 22, 2013.
  3. US Food and Drug Administration. What donor testing is required for different types of cells and tissues? 21 CFR sec 1271.85(a)-(c) (2005). http://www.accessdata.fda.gov/scripts/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?fr=1271.85. Accessed November 22, 2013. The regulations require anonymously donated gametes to be tested for the following diseases: human immunodeficiency virus, type 1; human immunodeficiency virus, type 2; hepatitis B virus; hepatitis C virus; treponema pallidum; human T-lymphotropic virus, type I; human T-lymphotropic virus, type II; cytomegalovirus; chlamydia trachomatis; and neisseria gonorrhea.
  4. US Food and Drug Administration. When do I register, submit an HCT/P list, and submit updates? 21 CFR sec 1271.21 (2001). http://www.accessdata.fda.gov/scripts/ cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=1271.21. Accessed November 22, 2013.
  5. US Food and Drug Administration. Tissue establishment registration. http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/ EstablishmentRegistration/TissueEstablishmentRegistration/ default.htm. Accessed September 8, 2013. The two-page form is available here: http://www.fda.gov/downloads/AboutFDA/ ReportsManualsForms/Forms/UCM082428.pdf. Accessed September 8, 2013.
  6. US Food and Drug Administration. What you should know—reproductive tissue donation. http://www.fda.gov/BiologicsBloodVaccines/ SafetyAvailability/TissueSafety/ ucm232876.htm. Accessed September 8, 2013.
  7. Knaplund KS. Synthetic cells, synthetic life, and inheritance. Valparaiso Law Rev. 2011;45(4):1371-1386.
  8. Pi VL. Regulating sperm donation: Why requiring exposed donation is not the answer. Duke J Gender Law Policy. 2009;16(2):379-401.
  9. Centers for Disease Control and Prevention. Assisted reproductive technology (ART): commonly asked questions about the US ART clinic reporting system. http://www.cdc.gov/art/ ART2010/faq.htm#2. Accessed September 8, 2013.
  10. Practice Committee of the American Society for Reproductive Medicine; Practice Committee of the Society for Assisted Reproductive Technology (ASRM/SART). Recommendations for gamete and embryo donation: a committee opinion. Fertil Steril. 2013;99(1):47-62.e1.
  11. ASRM/SART, 49, 50, 54, 55, 62.e1.
  12. ASRM/SART, 60.
  13. ASRM/SART, 59.
  14. Cone KL. Family law—egg donation and stem cell research—eggs for sale: The scrambled state of legislation in the human egg market. University of Arkansas at Little Rock Law Rev. 2012;35(1):189-216.
  15. Informed consent for egg donation; requirements; unprofessional conduct, Ariz Rev Stat Ann sec 36-1702 (West 2010).
  16. Oocyte donation; advertisement; screening process; procedures, Cal Health and Safety Code sec 125325 (West 2010).
  17. Informed consent, NY Comp Codes R & Regs title 10, sec 52-8.8(a) (2000).
  18. Suter SM. The politics of information: informed consent in abortion and end-of-life decision making. Am J Law Med. 2013;39(1):7-61.
  19. Kenney NJ, McGowan ML. Looking back: egg donors’ retrospective evaluations of their motivations, expectations, and experiences during their first donation cycle. Fertil Steril. 2010;93(2):455-466.
  20. Almeling R. Sex Cells: The Medical Market for Eggs and Sperm. Berkeley: University of California Press; 2011.
  21. Belkin L. An egg donor’s tale. Motherlode. New York Times. January 10, 2011. http://parenting.blogs.nytimes.com/2011/ 01/10/an-egg-donors-tale/?_r=1. Accessed November 25, 2013.
  22. Kramer W, Cahn N. Finding Our Families: A First-of-Its-Kind Book for Donor-Conceived People and Their Families. New York, NY: Avery Trade; 2013.
  23. The Organ Procurement and Transplantation Network. Guidance for the informed consent of living donors. http://optn.transplant.hrsa.gov/ContentDocuments/ Guidance_InformedConsentLiving_Donors.pdf. Accessed September 8, 2013.
  24. Krawiec KD. Sunny samaritans and egomaniacs: price-fixing in the gamete market. Law Contemp Probl. 2009;72(3):59-90.
  25. Skillern A, Cedars M, Huddleston H. Egg Donor Informed Consent Tool (EDICT): development and validation of a new informed consent tool for oocyte donors. Fertil Steril. 2013;99(6):1733-1738.
  26. Skillern, Cedars, Huddleston, 1734.
  27. ASRM/SART, 58.
  28. Schneider J. Fatal colon cancer in a young egg donor: a physician mother’s call for follow-up and research on the long-term risks of ovarian stimulation. Fertil Steril. 2008;90(5):2016.e1-e5.
  29. Kramer W, Schneider J, Schultz N. US oocyte donors: a retrospective study of medical and psychosocial issues. Hum Reprod. 2009;24(12):3144-3149.
  30. Schaefer GO, Sinaii N, Grady C. Informing egg donors of the potential for embryonic research: a survey of consent forms from US in vitro fertilization clinics. Fertil Steril. 2012;97(2):427-433.
  31. ASRM/SART, 55.
  32. Practice Committee of the American Society for Reproductive Medicine. Repetitive oocyte donation. Fertil Steril. 2008;90(5 Suppl):S194-S195.
  33. Campo-Englestein L. Why we need oversight for egg donation. Bioethics Today. June 17, 2013. http://www.amc.edu/bioethicsblog/post.cfm/ why-we-need-oversight-for-egg-donation. Accessed November 22, 2013.
  34. ASRM/SART, 53, 58.
  35. Levine AD. Self-regulation, compensation, and the ethical recruitment of oocyte donors. Hastings Cent Rep. 2010;40(2):25-36.
  36. Alberta HB, Berry RM, Levine AD. Risk disclosure and the recruitment of oocyte donors: are advertisers telling the full story? [draft].
  37. Alberta HB, Berry RM, Levine AD. Compliance with donor age recommendations in oocyte donor recruitment advertisements in the USA. Reprod Biomed Online. 2013;26(4):400-405.

Naomi Cahn, JD, is the Harold H. Greene Professor of Law at George Washington University in Washington, DC, and the co-author of Finding Our Families: A First-of-its-Kind Book for Donor-Conceived People and their Families (2013).

Jennifer Collins, JD, is the vice provost at Wake Forest University and a professor at Wake Forest Law School in Winston-Salem, North Carolina. She is the co-author of Privilege or Punish: Criminal Justice and the Challenge of Family Ties (2009).

Acknowledgments

Our thanks to June Carbone, Jodi LeBolt, Kimberly Krawiec, Ana Iltis, Jody Madeira, and Aaron Levine for inspiration and comments.

Read a response by Susan L. Crockin and Judith Daar to this article in the April issue of Virtual Mentor.

Egg-Donor Price Fixing and Kamakahi v. American Society for Reproductive Medicine, January 2014

AMA Code of Medical Ethics’ Opinions on Assisted Reproductive Technology, January 2014

Disclaimer

The people and events in this case are fictional. Resemblance to real events or to names of people, living or dead, is entirely coincidental.

The viewpoints expressed on this site are those of the authors and do not necessarily reflect the views and policies of the AMA.